Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia
Lada Beara-Lasic1,3, Michael H Pillinger2,3, David S Goldfarb1,31Divisions of Nephrology and 2Rheumatology, Department of Medicine, NYU Langone Medical Center, New York, NY, USA; 3Department of Medicine, New York Harbor VA Health Care System, New York, NY, USAAbstract: Gout recently passed rheumatoi...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-02-01
|
| Series: | International Journal of Nephrology and Renovascular Disease |
| Online Access: | http://www.dovepress.com/advances-in-the-management-of-gout-critical-appraisal-of-febuxostat-in-a3952 |
| _version_ | 1811287899642003456 |
|---|---|
| author | Lada Beara-Lasic Michael H Pillinger David S Goldfarb |
| author_facet | Lada Beara-Lasic Michael H Pillinger David S Goldfarb |
| author_sort | Lada Beara-Lasic |
| collection | DOAJ |
| description | Lada Beara-Lasic1,3, Michael H Pillinger2,3, David S Goldfarb1,31Divisions of Nephrology and 2Rheumatology, Department of Medicine, NYU Langone Medical Center, New York, NY, USA; 3Department of Medicine, New York Harbor VA Health Care System, New York, NY, USAAbstract: Gout recently passed rheumatoid arthritis to become the most common inflammatory arthritis in the United States (US). However, epidemiologic studies indicate that the quality of gout management is suboptimal owing to both patient and physician issues. Only three options for urate-lowering therapy are currently available in the US: allopurinol, probenecid, and recently, febuxostat. Probenecid is generally safe except for the occurrence of urolithiasis, but is only effective for the subset of patients with better kidney function. Allopurinol use is limited due to its side effects, potential toxicity of uncertain magnitude in patients with renal disease, and failure to achieve targeted serum urate levels. In part this failure may be due to the necessity for it to be titrated for optimal therapeutic effect. Febuxostat is a new medication that may offer several advantages and can be given as an alternative to allopurinol. We review the basic biology and clinical performance of febuxostat, and consider the potential utility of this agent in comparison to the older, better-established gout therapeutics.Keywords: allopurinol, gout suppressants, nephrolithiasis, uric acid, urolithiasis |
| first_indexed | 2024-04-13T03:27:34Z |
| format | Article |
| id | doaj.art-b8ea8abca2f249e19173e57f3ea90f97 |
| institution | Directory Open Access Journal |
| issn | 1178-7058 |
| language | English |
| last_indexed | 2024-04-13T03:27:34Z |
| publishDate | 2010-02-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of Nephrology and Renovascular Disease |
| spelling | doaj.art-b8ea8abca2f249e19173e57f3ea90f972022-12-22T03:04:37ZengDove Medical PressInternational Journal of Nephrology and Renovascular Disease1178-70582010-02-012010default110Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemiaLada Beara-LasicMichael H PillingerDavid S GoldfarbLada Beara-Lasic1,3, Michael H Pillinger2,3, David S Goldfarb1,31Divisions of Nephrology and 2Rheumatology, Department of Medicine, NYU Langone Medical Center, New York, NY, USA; 3Department of Medicine, New York Harbor VA Health Care System, New York, NY, USAAbstract: Gout recently passed rheumatoid arthritis to become the most common inflammatory arthritis in the United States (US). However, epidemiologic studies indicate that the quality of gout management is suboptimal owing to both patient and physician issues. Only three options for urate-lowering therapy are currently available in the US: allopurinol, probenecid, and recently, febuxostat. Probenecid is generally safe except for the occurrence of urolithiasis, but is only effective for the subset of patients with better kidney function. Allopurinol use is limited due to its side effects, potential toxicity of uncertain magnitude in patients with renal disease, and failure to achieve targeted serum urate levels. In part this failure may be due to the necessity for it to be titrated for optimal therapeutic effect. Febuxostat is a new medication that may offer several advantages and can be given as an alternative to allopurinol. We review the basic biology and clinical performance of febuxostat, and consider the potential utility of this agent in comparison to the older, better-established gout therapeutics.Keywords: allopurinol, gout suppressants, nephrolithiasis, uric acid, urolithiasishttp://www.dovepress.com/advances-in-the-management-of-gout-critical-appraisal-of-febuxostat-in-a3952 |
| spellingShingle | Lada Beara-Lasic Michael H Pillinger David S Goldfarb Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia International Journal of Nephrology and Renovascular Disease |
| title | Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia |
| title_full | Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia |
| title_fullStr | Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia |
| title_full_unstemmed | Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia |
| title_short | Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia |
| title_sort | advances in the management of gout critical appraisal of febuxostat in the control of hyperuricemia |
| url | http://www.dovepress.com/advances-in-the-management-of-gout-critical-appraisal-of-febuxostat-in-a3952 |
| work_keys_str_mv | AT ladabearalasic advancesinthemanagementofgoutcriticalappraisaloffebuxostatinthecontrolofhyperuricemia AT michaelhpillinger advancesinthemanagementofgoutcriticalappraisaloffebuxostatinthecontrolofhyperuricemia AT davidsgoldfarb advancesinthemanagementofgoutcriticalappraisaloffebuxostatinthecontrolofhyperuricemia |